HK2 and breast carcinoma: HK2 is mainly expressed in insulin-sensitive tissues and predominant in malignant or rapidly proliferating tumors (such as cervical cancer, breast cancer, lung cancer, prostate cancer, hepatocyte cell cancer), deleting HK2 inhibits tumor progression with no sign of adverse physiological effects [15–17].